Cardiff Oncology, Inc. (CRDF) — SEC Filings
Cardiff Oncology, Inc. (CRDF) — 23 SEC filings. Latest: 10-Q (Nov 6, 2025). Includes 8 8-K, 6 10-Q, 2 DEFA14A.
View Cardiff Oncology, Inc. on SEC EDGAR
Overview
Cardiff Oncology, Inc. (CRDF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Cardiff Oncology, Inc. (CRDF) reported a net loss of $11.258 million for the three months ended September 30, 2025, a slight improvement from the $11.855 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss widened to $38.635 million from $33.644 mi
Sentiment Summary
Across 23 filings, the sentiment breakdown is: 2 bearish, 21 neutral. The dominant filing sentiment for Cardiff Oncology, Inc. is neutral.
Filing Type Overview
Cardiff Oncology, Inc. (CRDF) has filed 6 10-Q, 8 8-K, 2 DEFA14A, 2 DEF 14A, 2 10-K, 2 SC 13G, 1 SC 13G/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (23)
Risk Profile
Risk Assessment: Of CRDF's 19 recent filings, 2 were flagged as high-risk, 8 as medium-risk, and 9 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $120K |
| Net Income | -$11.258M |
| EPS | N/A |
| Debt-to-Equity | 0.31 |
| Cash Position | $60.6M |
| Operating Margin | -99.0% |
| Total Assets | $63.780M |
| Total Debt | $14.990M |
Key Executives
- Dr. Michael H. Kalos
- Dr. Steven M. Altschuler
- Mr. David M. E. Smith
Industry Context
Cardiff Oncology operates in the highly competitive biotechnology sector, focusing on developing novel cancer therapies. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success often hinges on groundbreaking scientific innovation and the ability to navigate complex clinical trials and approval processes.
Top Tags
corporate-governance (5) · biotech (5) · Biotechnology (4) · 10-Q (4) · financials (3) · proxy-statement (3) · 8-K (3) · Cardiff Oncology (3) · Oncology (2) · Clinical Trials (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net loss for Q3 2025 | $11.258M | Improved from $11.855M in Q3 2024 |
| Net loss for nine months ended Sept 30, 2025 | $38.635M | Widened from $33.644M in the prior year period |
| Cash, cash equivalents and short-term investments | $60.6M | As of September 30, 2025, down from $91.746M at Dec 31, 2024 |
| Royalty revenues for Q3 2025 | $120K | Decreased from $165K in Q3 2024 |
| Research and development expenses for nine months ended Sept 30, 2025 | $30.254M | Increased from $27.140M in the prior year period |
| Selling, general and administrative expenses for nine months ended Sept 30, 2025 | $11.229M | Increased from $9.471M in the prior year period |
| Common Stock shares outstanding | 67,360,564 | As of October 30, 2025 |
| Net Loss | $14.1M | Increased by 16.5% from $12.1M in Q2 2024 |
| Research and Development Expenses | $10.9M | Increased from $9.4M in Q2 2024, reflecting higher clinical trial costs |
| Cash and Marketable Securities | $78.9M | Decreased from $107.8M at December 31, 2024, indicating significant cash burn |
| Revenue Growth | 0% | No revenue reported for Q2 2025, consistent with pre-commercial stage |
| Six-Month Net Loss Increase | 15.2% | Net loss for six months ended June 30, 2025, rose to $28.1M from $24.4M in 2024 |
| Report Date | 20250613 | Date of earliest event reported |
| SEC File Number | 001-35558 | Cardiff Oncology's SEC file number |
| Reporting Period | Q1 2025 | First quarter of 2025 financial data |
Frequently Asked Questions
What are the latest SEC filings for Cardiff Oncology, Inc. (CRDF)?
Cardiff Oncology, Inc. has 23 recent SEC filings from Jan 2024 to Nov 2025, including 8 8-K, 6 10-Q, 2 DEFA14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CRDF filings?
Across 23 filings, the sentiment breakdown is: 2 bearish, 21 neutral. The dominant sentiment is neutral.
Where can I find Cardiff Oncology, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Cardiff Oncology, Inc. (CRDF) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Cardiff Oncology, Inc.?
Key financial highlights from Cardiff Oncology, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CRDF?
The investment thesis for CRDF includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Cardiff Oncology, Inc.?
Key executives identified across Cardiff Oncology, Inc.'s filings include Dr. Michael H. Kalos, Dr. Steven M. Altschuler, Mr. David M. E. Smith.
What are the main risk factors for Cardiff Oncology, Inc. stock?
Of CRDF's 19 assessed filings, 2 were flagged high-risk, 8 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Cardiff Oncology, Inc.?
Forward guidance and predictions for Cardiff Oncology, Inc. are extracted from SEC filings as they are enriched.